Evidence map›Paper›PMID 32745474›Full record

ArticleJournal of immunological methods

Characterization of CAR T cell expansion and cytotoxic potential during Ex Vivo manufacturing using image-based cytometry.

Colby R Maldini, Andrea C Love, Kevin W Tosh, Leo Li-Ying Chan, Kevin Gayout, Tim Smith, James L Riley

Abstract read
In one paragraph

Article in Journal of immunological methods. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Optimal pairing of binder and co-stimulatory domains improves dual CART cell efficacy.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Colby R MaldiniDepartment of Microbiology, Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Andrea C LoveDepartment of Technology R&D, Nexcelom Bioscience LLC, Lawrence, MA 01843, USA.
Kevin W ToshDepartment of Microbiology, Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Leo Li-Ying ChanDepartment of Technology R&D, Nexcelom Bioscience LLC, Lawrence, MA 01843, USA.
Kevin GayoutDepartment of Microbiology, Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Tim SmithDepartment of Technology R&D, Nexcelom Bioscience LLC, Lawrence, MA 01843, USA.
James L RileyDepartment of Microbiology, Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: rileyj@upenn.edu.

Funding

Virus & Reservoirs CoreP30AI045008 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI ROBERT GROSS · 1999 to 2026
$78.6M
First-in-human study of two anti-SARS CoV-2 antibodies in health volunteersUM1AI126620 · NIAID · WISTAR INSTITUTE · PI MONTANER, LUIS J, RILEY, JAMES L. · 2016 to 2021
$24.5M
IMMUNOBIOLOGY OF NORMAL AND NEOPLASTIC LYMPHOCYTEST32CA009140 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Malay Haldar, WARREN S PEAR · 1985 to 2026
$16.1M
Modeling HIV CAR-T cell trafficking and persistence in Non-Human PrimatesU19AI149680 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI RILEY, JAMES L. · 2020 to 2024
$13.2M
Sequencing and Viral Evolution CoreU19AI117950 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI WHERRY, E. JOHN · 2015 to 2019
$12.0M
TRAINING IN HIV PATHOGENESIST32AI007632 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Frederic D Bushman, James L. Riley · 2000 to 2026
$10.6M
Microphysiological systems for modeling autoimmunity in type 1 diabetesUG3DK122644 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI GADUE, PAUL J, HUH, DONGEUN · 2019 to 2020
$2.3M
NCI NIH HHS T32 CA009140NIAID NIH HHS P30 AI045008NIAID NIH HHS T32 AI007632NIAID NIH HHS U19 AI117950NIAID NIH HHS U19 AI149680NIAID NIH HHS UM1 AI126620NIDDK NIH HHS UG3 DK122644
6 · The paper itself

Abstract

Since the FDA approval of two Chimeric Antigen Receptor (CAR) T cell therapies against CD19

Indexed as

Cell ProliferationCytotoxicity, ImmunologicFlow CytometryImmunotherapy, AdoptiveMicroscopy, FluorescenceAntigens, CDCoculture TechniquesHumansK562 CellsKineticsLeukemia, MyeloidReceptors, Chimeric AntigenT-LymphocytesWorkflowAntigens, CDReceptors, Chimeric AntigenBioluminescence (BLI)-based cytotoxicity assayCAR T cell manufacturingCell-mediated cytotoxicityChimeric antigen receptor (CAR) T cellsImage cytometry

Identifiers

PMID32745474
PMCPMC7487036

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.